|
PMS2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
5.574900E-04 |
| Normal-vs-Stage3 |
1.55431223447522E-15 |
| Normal-vs-Stage4 |
1.63691282750733E-12 |
| Stage1-vs-Stage2 |
4.243700E-03 |
| Stage1-vs-Stage3 |
1.454830E-01 |
| Stage1-vs-Stage4 |
4.426000E-02 |
| Stage2-vs-Stage3 |
2.585000E-04 |
| Stage2-vs-Stage4 |
1.572010E-04 |
| Stage3-vs-Stage4 |
4.461000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
7.59689999796365E-08 |
| Normal-vs-Asian |
1.79356529628194E-12 |
| Caucasian-vs-AfricanAmerican |
9.822600E-01 |
| Caucasian-vs-Asian |
6.730200E-01 |
| AfricanAmerican-vs-Asian |
8.446400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.93323176648164E-12 |
| Normal-vs-Female |
1.6242562850266E-12 |
| Male-vs-Female |
3.164200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.99840144432528E-15 |
| Normal-vs-Age(61-80Yrs) |
6.02020000517456E-09 |
| Normal-vs-Age(81-100Yrs) |
9.85380000000369E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.642000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.421800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.149200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.070020E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.119800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.801200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.82479994740248E-09 |
| Classical-VS-Follicular |
2.16659999999758E-05 |
| Classical-VS-Other |
8.502400E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
8.98170426921752E-14 |
| Tall-VS-Other |
8.381600E-02 |
| Tall-VS-Normal |
1.62458935193399E-12 |
| Follicular-VS-Other |
2.251600E-01 |
| Follicular-VS-Normal |
6.18500000000299E-05 |
| Other-VS-Normal |
6.643700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.94431187500777E-12 |
| Normal-vs-N1 |
1.55431223447522E-15 |
| N0-vs-N1 |
6.401200E-04 |
|
|
